Skip to main content
. 2022 Apr 27;52:102322. doi: 10.1016/j.redox.2022.102322

Fig. 5.

Fig. 5

NAG-1/GDF15 inhibits hepatic steatosis in the FFA-induced hepatocellular steatosis model. (A–B) Representative Oil Red O staining of lipid droplets accumulation in HepG2 (A) and Huh-7 (B) cells as transfected with pcDNA3.1-NAG-1 plasmid with or without FFA treatment. Scale bar, 100 μm. (C) Quantitative analysis of Oil Red O staining in HepG2 and Huh-7 cells as transfected with pcDNA3.1-NAG-1 plasmid with or without FFA treatment. (D) Intracellular TG content in HepG2 and Huh-7 cells as transfected with pcDNA3.1-NAG-1 plasmid. (E–F) Representative Oil Red O staining of lipid droplets accumulation in HepG2 (E) and Huh-7 (F) cells as transfected with NAG-1 siRNA with or without FFA treatment. Scale bar, 100 μm. (G) Quantitative analysis of Oil Red O staining in HepG2 and Huh-7 cells as transfected with NAG-1 siRNA with or without FFA treatment. (H) Intracellular TG content in HepG2 and Huh-7 cells as transfected with NAG-1 siRNA. (I–L) Representative Bodipy 493/503 fluorescence staining of lipid droplets accumulation and quantitative analysis in HepG2 cells as transfected with pcDNA3.1-NAG-1 plasmid (I) or NAG-1 siRNA (K) and in Huh-7 cells as transfected with pcDNA3.1-NAG-1 plasmid (J) or NAG-1 siRNA (L) with or without FFA treatment. Scale bar, 20 μm. Data are shown as means ± SEM from three independent experiments. Statistical analysis was performed using one-way ANOVA followed by Bonferroni's post hoc test (n = 3). *P < 0.05, **P < 0.01, ***P < 0.001 vs empty vector or negative control of siRNA, without FFA treatment, #P < 0.05, ##P < 0.01 ###P < 0.001 vs empty vector or negative control of siRNA, with FFA treatment. (For interpretation of the references to colour in this figure legend, the reader is referred to the Web version of this article.)